Emile Voest
More and more cancer drugs are only suitable for a small group of patients. However, we are often not capable to find these patients. That is why every patient with metastatic cancer should be genetically screened before starting treatment.
Back to newsMore news
GLOW: working toward more treatment options for glioblastoma
The outlook for patients with glioblastoma has been unfavorable for years, and treatment options remain limited. That is a reason …
Unraveling of genetic mechanism behind tumor formation may improve targeted treatment for cancer patients
Genetic alterations in the FGFR2 gene occur in various cancer types and represent a promising target for therapies. However, clinical …
Join us for an evening of Healthcare Tech innovation with Hartwig Medical Foundation and GCUG
Calling all software developers and tech enthusiasts 🚀 Hartwig Medical Foundation partners with Google Cloud User Group (GCUG) to bring …
In our profession, we need to know everything about the patient, but we also want to know as much as possible about the patient’s tumor.